Precision therapeutic strategies for Hodgkin lymphoma
Pages: 372-375
Year: 2017 Issue: 6
Journal: Journal of Leukemia & Lymphoma
Abstract: Hodgkin lymphoma (HL) is a rare subtype of B-cell malignancies, and it often occurs in the youth. About 80 % patients can be cured with the advance of modern therapy. How to further improve the cure rate of HL and minimize adverse reactions are new tasks faced by the clinicians, meanwhile, short-term curative effect and long-term survival rate are worthy of attention. An accurate assessment of disease stage is crucial for the selection of the appropriate therapy. This review discusses the hot issues regarding HL treatments to further improve the precision therapeutics, and to provide more references for clinical treatment.
Year: 2017 Issue: 6
Journal: Journal of Leukemia & Lymphoma
Abstract: Hodgkin lymphoma (HL) is a rare subtype of B-cell malignancies, and it often occurs in the youth. About 80 % patients can be cured with the advance of modern therapy. How to further improve the cure rate of HL and minimize adverse reactions are new tasks faced by the clinicians, meanwhile, short-term curative effect and long-term survival rate are worthy of attention. An accurate assessment of disease stage is crucial for the selection of the appropriate therapy. This review discusses the hot issues regarding HL treatments to further improve the precision therapeutics, and to provide more references for clinical treatment.
Related Articles